Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.61 |
| ▸ | PTGES | O14684 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18467072 | 0.84 | PTGS2 (0.68) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL8266070 | 0.84 | PTGS2 (0.80) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL14562085 | 0.83 | KDM4C (0.42) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL25150243 | 0.83 | PTGS2 (0.72) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL14562086 | 0.82 | SMPD1 (0.43) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL14280460 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL5420747 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL14747609 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1CYP2C9PDPK1HDAC3 | |
| SCHEMBL14418045 | 0.80 | PDPK1 (0.66) | PTGS2PTGS1PDPK1CA9 | |
| SCHEMBL15424743 | 0.80 | PTGS2 (0.63) | PTGS2PTGS1CYP2C9PDPK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9775906-B2 | Hydrogel polymeric compositions and methods | INCEPT LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-9125807-B2 | Adhesive hydrogels for ophthalmic drug delivery | INCEPT LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-8409606-B2 | Drug delivery through hydrogel plugs | INCEPT, LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20100209478-A1 | DRUG DELIVERY THROUGH HYDROGEL PLUGS | OCULAR THERAPEUTIX, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-7659426-B2 | Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090252781-A1 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS | INCEPT LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
| US-20090017097-A1 | Hydrogel polymeric compositions and methods | OCULAR THERAPEUTIX, INC. | 2009-01-15 | — | — | US | disclosed |
| US-20080306146-A1 | Dosing Regimens for Cox-2 Inhibitor | AMOREPACIFIC CORPORATION (KR) | 2008-12-11 | — | — | US | disclosed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080027011-A1 | Homogeneous paste and gel formulations | MERIAL LIMITED | 2008-01-31 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070082955-A1 | Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252781-A1 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS | CRYAA, CRYAB, UACA | PTGS2 368/4885PTGS1 268/4885CYP2C9 4277/4885 |
| US-20080027011-A1 | Homogeneous paste and gel formulations | EPX, CAT, PEF1 | PTGS2 329/4885PTGS1 101/4885CYP2C9 1064/4885 |
| US-20070082955-A1 | Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto | SRPRB, KHSRP, SPG11 | PTGS2 4079/4885PTGS1 3661/4885CYP2C9 4881/4885 |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | LPL, ALOX12, LCLAT1 | PTGS2 9/4885PTGS1 26/4885CYP2C9 392/4885 |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | KCNN3, KCNN1, KCNN2 | PTGS2 594/4885PTGS1 558/4885CYP2C9 1249/4885 |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | CYP3A4, CYP4B1, CYP2E1 | PTGS2 270/4885PTGS1 84/4885CYP2C9 79/4885 |
| US-20080306146-A1 | Dosing Regimens for Cox-2 Inhibitor | PTGES2, PTGS2, PTGER2 | PTGS2 2/4885PTGS1 4/4885CYP2C9 77/4885 |
| US-20100209478-A1 | DRUG DELIVERY THROUGH HYDROGEL PLUGS | AQP1, AQP4, AQP3 | PTGS2 366/4885PTGS1 279/4885CYP2C9 1404/4885 |
| US-20090017097-A1 | Hydrogel polymeric compositions and methods | CRYAA, CRYAB, UACA | PTGS2 368/4885PTGS1 268/4885CYP2C9 4277/4885 |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | PTGS2, CA2, PTGES2 | PTGS2 1/4885PTGS1 4/4885CYP2C9 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.